New combo therapy shows promise for tough breast cancers
NCT ID NCT03802604
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 34 times
Summary
This study tested a combination of two drugs, T-VEC and atezolizumab, in 28 women with early-stage breast cancer that still had tumor left after standard chemotherapy. The goal was to see if this treatment could shrink or eliminate the remaining cancer before surgery. The approach aims to boost the immune system to fight the cancer more effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centro Integral Oncológico Clara Campal
Madrid, Madrid, 28050, Spain
-
Hospital Clínic de Barcelona
Barcelona, 08036, Spain
-
Hospital Clínico universitario de Valencia
Valencia, Valencia, 46010, Spain
-
Hospital Universitari Vall d'Hebrón
Barcelona, Barcelona, 08035, Spain
Conditions
Explore the condition pages connected to this study.